Thermo Fisher in talks to buy Patheon: Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
Go back to Thermo Fisher in talks to buy Patheon: Bloomberg
May 16, 2017 7:25 AM EDT
Jefferies reiterated a Hold rating and $175.00 price target on Thermo Fisher Scientific (NYSE: TMO) following the company's announced move to acquire PTHN. TMO is paying $35/sh in cash and assuming ~$2B of net debt, implying an EV of $7.2B.
The deal marks... More
May 15, 2017 7:02 AM EDT
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transaction represents a purchase price of approximately $7.2 billion, which includes the assumption of approximately $2.0 billion of net... More
May 15, 2017 6:22 AM EDT
Thermo Fisher Scientific (NYSE: TMO) is in talks to acquire Patheon N.V. (NYSE: PTHN), according to Bloomberg, citing people with knowledge of the matter. An agreement could be reached as early as this week.
...
More
